Systemic lupus erythematosus, complicated with refractory skin ulcers, treated successfully with bosentan

Modern Rheumatology

Volumn 19, Issue 4, 2009, Pages 447-451

  Suzuki, Eiji ^a   Kyozuka, Hyo ^a   Nishida, Toru ^a   Kanno, Takashi ^a   Ohira, Hiromasa ^b  

^a OHTA NISHINOUCHI HOSPITAL   (Japan)

^b FUKUSHIMA MEDICAL UNIVERSITY   (Japan)

Author keywords

Bosentan; Endothelin; Pulmonary hypertension (PH); Skin ulcer; Systemic lupus erythematosus (SLE)

Indexed keywords

ACETYLSALICYLIC ACID; ALANINE AMINOTRANSFERASE; ANTIBIOTIC AGENT; ANTINUCLEAR ANTIBODY; ASPARTATE AMINOTRANSFERASE; BERAPROST; BOSENTAN; BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C4; CYCLOSPORIN; D DIMER; DOUBLE STRANDED DNA ANTIBODY; FIBRINOGEN; FIBRINOGEN DEGRADATION PRODUCT; LACTATE DEHYDROGENASE; PREDNISOLONE; RECOMBINANT BASIC FIBROBLAST GROWTH FACTOR; RIBONUCLEOPROTEIN ANTIBODY; RO ANTIBODY;

ABSENCE OF SIDE EFFECTS; ADULT; ARTICLE; CASE REPORT; DEBRIDEMENT; DIFFERENTIAL DIAGNOSIS; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG EFFICACY; DYSPNEA; ECHOCARDIOGRAPHY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FOOT EDEMA; HEART DILATATION; HEART PALPITATION; HUMAN; HUMAN TISSUE; LUNG AUSCULTATION; LUNG SCINTISCANNING; LYMPHOCYTE COUNT; MIXED CONNECTIVE TISSUE DISEASE; MOUTH ULCER; PHLEGMON; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PULMONARY HYPERTENSION; RASH; SKIN BIOPSY; SKIN ULCER; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTOLIC BLOOD PRESSURE; THORAX RADIOGRAPHY; TRICUSPID VALVE REGURGITATION; ULCER HEALING; VASCULITIS; WOUND IRRIGATION;

ADULT; ANTIHYPERTENSIVE AGENTS; EXTREMITIES; FEMALE; HUMANS; HYPERTENSION, PULMONARY; LUPUS ERYTHEMATOSUS, SYSTEMIC; SKIN ULCER; SULFONAMIDES; TREATMENT OUTCOME;

EID: 68549096007     PISSN: 14397595     EISSN: 14397609     Source Type: Journal    
DOI: 10.1007/s10165-009-0184-y     Document Type: Article

References (19)

1. Hoeper MM. Pulmonary hypertension in collagen vascular disease. Eur Respir J. 2002;19:571-6.
2. Richard NC, Gerald S, Olivier S, Ivan MR, Adaani F, Victor FT, et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: A randomised placebo-controlled study. Lancet. 2001;358:1119-23.
3. Sontheimer RD. Systemic lupus erythematosus and the skin. In: Lahita RG, editor. Systemic lupus erythematosus. 3rd ed. San Diego: Academic Press; 1999. p. 631-56.
4. Korn JH, Mayers M, Matucci Cerinic M, Rainisio M, Pope J, Hachulla E, et al. Digital ulcer in systemic sclerosis: Prevention by treatment with bosentan, an oral endothelin receptor antagonist. Arthritis Rheum. 2004;50:3985-93.
5. Tan EM, Cohen AS, Fries JF, Masi AT, Mcshane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982;25:1271-7.
6. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997;40:1725.
7. Lawrence EC. Systemic lupus erythematosus and the lung. In: Lahita RG, editor. Systemic lupus erythematosus. 3rd ed. San Diego: Academic Press; 1999. p. 719-31.
8. Travis WD, Colby TV, Koss MN, Rosado-de-Christenson ML, Muller NL, King TE Jr. Pulmonary hypertension and other vascular disorders. Atlas of nontumor pathology: Non-neoplastic disorders of the lower respiratory tract. Washington: American Registry of Pathology and the Armed Forces Institute of Pathology; 2002. p. 767-92.
9. MacLean MR. Endothelin-1: A mediator of pulmonary hypertension. Pulm Pharmacol Ther. 1998;11:125-32.
10. Giaid A, Yanagisawa M, Langleben D, Michel RP, Levy R, Shennib H, et al. Expression of endothelin-1 in the lung of patients with pulmonary hypertension. N Engl J Med. 1993;328:1732-9.
11. Rubens C, Ewert R, Halank M, Wensel R, Orzechowski HD, Schuitheiss HP, et al. Big endothelin-1 and endothelin-1 plasma levels are correlated with the severity of primary pulmonary hypertension. Chest. 2001;120:1562-9.
12. Abraham DJ, Vancheeswaran R, Dashwood MR, Rajkumar VS, Pantelides P, Shi-wen X, et al. Increased levels of endothelin-1 and differential endothelin type A and B receptor expression in scleroderma-associated fibrotic lung disease. Am J Pathol. 1997;151:831-41.
13. Rubin LJ, Badesch DB, Barst RJ, Galie N, Black CM, Keogh A, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med. 2002;346:896-903.
14. Humbert M, Stibon O, Simonneau G. Treatment of pulmonary arterial hypertension. N Engl J Med. 2004;351:1425-36.
15. Galie N, Rubin L, Hoeper M, Jansa P, Al-Hiti H, Meyer G, et al. Treatment of mildly symptomatic pulmonary arterial hypertension with bosentan: A double-blind, randomised controlled study. Lancet. 2008;371:2093-100.
16. Rowell NR, Goodfield MJD. The 'Connective tissue diseases'. In: Champion RH, Burton JL, Burns DA, Breathnach SM, editors. Rook/Wilkinson/Ebling textbook of dermatology. 6th ed. Oxford: Blackwell Science; 1997. p. 2437-575.
17. Humbert M, Cabane J. Successful treatment of systemic sclerosis digital ulcers and pulmonary arterial hypertension with endothelin receptor antagonist bosentan. Rheumatology. 2003;42:191-3.
18. Garcia de Pena-Lefebvre P, Rodriguez Rubio S, Valero Exposito M, Carmona L, Gamir ML, Beltran Gutierrez J, et al. Long-term experience of bosentan for treating ulcers and healed ulcers in systemic sclerosis patients. Rheumatology. 2008;47:464-6.
19. Mayes MD. Endothelin and endothelin receptor antagonist in systemic rheumatic disease. Arthritis Rheum. 2003;48:1190-9.